Verrica Pharmaceuticals (NASDAQ:VRCA) Trading 0.9% Higher

Verrica Pharmaceuticals Inc. (NASDAQ:VRCAGet Free Report) shares traded up 0.9% during trading on Monday . The stock traded as high as $7.96 and last traded at $7.70. 97,191 shares traded hands during trading, a decline of 48% from the average session volume of 188,376 shares. The stock had previously closed at $7.63.

Analyst Ratings Changes

Several analysts have commented on the company. Needham & Company LLC increased their target price on Verrica Pharmaceuticals from $8.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. HC Wainwright raised their price target on Verrica Pharmaceuticals from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th.

Check Out Our Latest Report on Verrica Pharmaceuticals

Verrica Pharmaceuticals Stock Up 0.9 %

The company has a market capitalization of $326.63 million, a PE ratio of -4.40 and a beta of 1.56. The company has a debt-to-equity ratio of 29.58, a current ratio of 3.17 and a quick ratio of 3.04. The company has a 50-day moving average of $8.08 and a two-hundred day moving average of $6.68.

Verrica Pharmaceuticals (NASDAQ:VRCAGet Free Report) last released its earnings results on Monday, May 13th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.10. The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $2.70 million. Verrica Pharmaceuticals had a negative return on equity of 229.26% and a negative net margin of 905.83%. Sell-side analysts anticipate that Verrica Pharmaceuticals Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Verrica Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Verrica Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock valued at $7,511,000 after acquiring an additional 7,609 shares during the period. Perceptive Advisors LLC raised its holdings in Verrica Pharmaceuticals by 40.9% during the fourth quarter. Perceptive Advisors LLC now owns 7,099,182 shares of the company’s stock valued at $51,966,000 after acquiring an additional 2,060,199 shares during the period. Avoro Capital Advisors LLC increased its holdings in shares of Verrica Pharmaceuticals by 35.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 3,999,999 shares of the company’s stock worth $29,280,000 after purchasing an additional 1,045,935 shares during the last quarter. Finally, BML Capital Management LLC increased its holdings in shares of Verrica Pharmaceuticals by 20.0% in the fourth quarter. BML Capital Management LLC now owns 180,000 shares of the company’s stock worth $1,318,000 after purchasing an additional 30,000 shares during the last quarter. 42.45% of the stock is owned by institutional investors.

About Verrica Pharmaceuticals

(Get Free Report)

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.

See Also

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.